RemeGen Tightens Controls After Delay in Disclosing Wealth Management Deals

The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).

RemeGen Co., Ltd. has disclosed that it purchased seven wealth management products from Shanghai Pudong Development Bank between April 28 and May 13, 2026, which, when aggregated under Hong Kong listing rules, triggered disclosure obligations as a discloseable transaction. The company admitted it failed to announce these transactions in a timely manner due to an oversight in monitoring its total exposure to a single bank and has outlined remedial measures, including stricter internal controls, updated monitoring lists and enhanced compliance procedures, to prevent future breaches.

Management emphasized that the non-compliance was inadvertent and that there was no intention to withhold information from investors or regulators. By strengthening reporting protocols and raising awareness among directors and key staff about notifiable transaction requirements, RemeGen aims to restore regulatory confidence and reduce the risk of similar lapses in its financial management practices.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong, focusing on the research, development and commercialization of innovative therapies. The company operates within the healthcare sector and manages surplus funds through wealth management products as part of its treasury activities.

Average Trading Volume: 4,190,666

Technical Sentiment Signal: Buy

Current Market Cap: HK$65.14B

For an in-depth examination of 9995 stock, go to TipRanks’ Overview page.